Feasibility and outcome of tandem stem cell autotransplants in multiple myeloma

Haematologica

Volumn 90, Issue 12, 2005, Pages 1643-1649

  Galli, Monica ^a   Nicolucci, Antonio ^b   Valentini, Miriam ^b   Belfiglio, Maurizio ^b   Delaini, Federica ^a   Crippa, Claudia ^a   Barbui, Anna Maria ^a   Giussani, Ursula ^a   Rambaldi, Alessandro ^a   Barbui, Tiziano ^a  

^a OSPEDALI RIUNITI   (Italy)

^b Laboratorio di Farmacologia ed Epidemiologia   (Italy)

Author keywords

Autotransplant; High dose therapy; Multiple myeloma; Outcomes research; Remission

Indexed keywords

ANTINEOPLASTIC AGENT; CARMUSTINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; MELPHALAN; PREDNISOLONE; VINCRISTINE;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; AUTOTRANSPLANTATION; CANCER CENTER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL FEATURE; CLINICAL PRACTICE; CLINICAL TRIAL; COHORT ANALYSIS; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DRUG MEGADOSE; FEASIBILITY STUDY; FEMALE; FOLLOW UP; HEALTH PROGRAM; HUMAN; INFECTION; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; REMISSION; STEM CELL TRANSPLANTATION; TOXICITY; TREATMENT OUTCOME; TUMOR DIAGNOSIS;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CASE MANAGEMENT; COHORT STUDIES; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DISEASE PROGRESSION; DOXORUBICIN; FEASIBILITY STUDIES; FEMALE; FOLLOW-UP STUDIES; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELL MOBILIZATION; HUMANS; LIFE TABLES; MALE; MELPHALAN; MIDDLE AGED; MULTIPLE MYELOMA; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PREDNISONE; SURVIVAL ANALYSIS; THALIDOMIDE; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME; VINCRISTINE; WHOLE-BODY IRRADIATION;

EID: 29144520522     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. The Myeloma Trialists' Collaborative Group. Combination chemotherapy versus melphalan plus prednisone as treatment of multiple myeloma: an overview of 6,633 patients from 27 randomized trials. J Clin Oncol 1998; 16:3832-42.
2. Kyle RA, Rajkumar SV. Multiple myeloma. N Engl J Med 2004;351:1860-73.
3. Barlogie B, Shaughnessy J, Tricot G, Jacobson J, Zangari M, Anaissie E, et al. Treatment of multiple myeloma. Blood 2004;103:20-32.
4. Barlogie B, Jagannath S, Desikan KR, Mattox S, Vesole D, Siegel D, et al. Total therapy I with tandem transplants for newly diagnosed multiple myeloma. Blood 1999;93:55-65.
5. Segeren CM, Sonneveld P, van der Holt B, Vellenga E, Croockewit AJ, Verhoef GE, et al. Overall and event-free survival are not improved by the use of myeloablative therapy following intensified chemotherapy in previously untreated patients with multiple myeloma: a prospective randomized phase 3 trial. Blood 2003;101:2144-51.
6. Attal M, Harousseau J-L, Facon T, Guilhot F, Doyen C, Fuzibet J-G et al. Single vs double autologous stem-cell transplantation for multiple myeloma. N Engl J Med 2003;349:2495-502.
7. Fermand JP. High dose therapy supported with autologous stem cell transplantation in multiple myeloma: long-term follow-up of the prospective studies of the MAG group. Haematologica 2005;90 Suppl 1):40.
8. Cavo M, Cellini C, Tosi P, Cangini D, Tacchetti P, de Vivo A, et al. Superiority of double over single autologous transplantation as first-line therapy for multiple myeloma. Haematologica 2005; 90 Suppl 3:33.
9. Zanetti R, Gafà L, Pannelli F, Conti E, Rosso S, eds. Cancer in Italy. Incidence data from cancer registries. III vol. 1993-1998. Roma: Il Pensiero Scientifico Editore. 2002.
10. Alexanian R, Haut A, Khan AU, Lane M, McKelvey EM, Migliore JP, et al. Treatment for multiple myeloma: combination chemotherapy with different melphalan dose regimens. JAMA 1969;208:1680-5.
11. Salmon SE, Haut A, Bonnet JD, Amare M, Weik JK, Durie BG, et al. Alternating combination chemotherapy and levamisole improves survival in mutiple myeloma: a Southwest Oncology Group study. J Clin Oncol 1983;1:453-61.
12. Palumbo A, Bringhen S, Bertola A, Cavallo F, Falco P, Massaia M, et al. Multiple myeloma: comparison of two dose-intensive melphalan regimens (100 vs 200 mg/m2). Leukemia 2004; 18:133-8.
13. Rambaldi A, Borleri G, Dotti G, Bellavita P, Amaru R, Biondi A, et al. Innovative two-step negative selection of granulocyte colony-stimulating factor-mobilized circulating progenitor cells: adequacy for autologous and allogeneic transplantation. Blood 1998; 91:2189-96.
14. Barbui AM, Galli M, Dotti G, Belli N, Boleri G, Gritti G, et al. Negative selection of peripheral blood stem cells to support a tandem autologous transplantation programme in multiple myeloma. Br J Haematol 2002;116: 202-10.
15. Moreau P, Facon T, Attal M, Hulin C, Michallet M, Maloisel E, et al. Comparison of 200 mg/m2 melphalan and 8 Gy total body irradiation plus 140 mg/m2 as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma. Final analysis of the IFM 95-02 randomized trial. Blood 2002;99:731-5.
16. Bladé J, Samson D, Reece D, Apperley J, Biorstrand B, Gahrton G, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haematopoietic stem cell transplantation. Br J Haematol 1998;102:1115-23.
17. Imrie K, Esmail R, Meyer MR. The role of high-dose chemotherapy and stem-cell transplantation in patients with multiple myeloma: a practice guideline of the Cancer Care Ontario Practice Guidelines Initiative. Ann Intern Med 2002;136:619-29.
18. Tricot G, Spencer T, Sawyer J, Spoon D, Desikan R, Fassas A, et al. Predicting long-term (>5 years) event-free survival in multiple myeloma patients following planned tandem autotransplants. Br J Haematol 2002;116:211-7.
19. Blade J, San Miguel JF, Fontanillas M, Alcala A, Maldonado J, Garcia-Conde J, et al. Survival of multiple myeloma patients who are potential candidates for early high-dose therapy intensification/autotransplantation and who were conventionally treated. J Clin Oncol 1996;14:2167-73.
20. Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999;341:1565-71.
21. Dumontet C, Ketterer N, Espinouse D, Neidhardt EM, Moullet I, Thieblemont C, et al. Reduced progression-free survival in elderly patients receiving intensification with autogolous peripheral blood stem cell reinfusion for multiple myeloma. Bone Marrow Transpl 1998;21:1037-41.
22. Alegre A, Diaz-Mediavilla J, San-Miguel J, Martinez R, Garcia Larana J, Sureda A, et al. Autologous peripheral blood stem cell transplantation for multiple myeloma: a report of 259 cases from the Spanish Registry. Bone Marrow Transpl 1998;21:133-40.
23. Majolino I, Vignetti M, Meloni G, Vegna ML, Scimè R, Tringali R, et al. Autologous transplantation in multiple myeloma: a GITMO retrospective analysis on 290 patients. Haematologica 1999;84:844-52.
24. Gertz MA, Lacy MQ, Inwards DJ, Gastineau DA, Tefferi A, Chen MG, et al. Delayed stell cell transplantation for the management of relapsed or refractory multiple myeloma. Bone Marrow Transpl 2000;26:45-50.
25. Nadal E, Gine E, Bladé J, Esteve J, Rosinol L, Fernandez-Aviles F, et al. High-dose therapy/autologous stem cell transplantation in patients with chemosensitive multiple myeloma: predictors of complete remission. Bone Marrow Transpl 2004;33:61-4.
26. Singhal S, Powles R, Sirohi B, Treleaven J, Kulkarni S, Mehta J. Response to induction chemotherapy is not essential to obtain survival benefit from high-dose melphalan and autotransplantation in myeloma. Bone Marrow Transpl 2002;30:673-9.
27. Terpos E, Apperley JF, Samson D, Giles C, Crawley C, Kanfer E, et al. Autologous stem cell transplantation in multiple myeloma: improved survival in nonsecretory multiple myeloma but lack of influence of age, status at transplant, previous treatment and conditioning regimen. A single-centre experience in 127 patients. Bone Marrow Transpl 2003;31:163-70.
28. Reece DE, Bredeson C, Perez WS, Jagannath S, Zhang MJ, Ballen KK, et al. Autologous stem cell transplantation in multiple myeloma patients < 60 vs > 60 years or age. Bone Marrow Transplant 2003;32:1135-43.
29. Shaughnessy J Jr, Trian E, Sawyer J, McCoy J, Tricot G, Jacobson J, et al. Prognostic impact of cytogenetic and interphase fluorescence in situ hybridization-defined chromosome 13 deletion in multiple myeloma: early results of total therapy II. Br J Haematol 2003;120:44-52.
30. Richardson P, Schlossman R, Weller E, Hideshima T, Mitsiades D, Davies FE, et al. Immunomodulatory derivative CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood 2002;100:3063-7.
31. Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003;348:2609-17.